CHRM1抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue, Primary antibody: P00270(CHRM1 Antibody) at dilution 1/375, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

The cholinergic receptor muscarinic 1 (CHRM1) antibody is a tool used to detect and study the M1 subtype of muscarinic acetylcholine receptors, which are G protein-coupled receptors (GPCRs) critical for mediating acetylcholine signaling in the central and peripheral nervous systems. CHRM1 is predominantly expressed in the brain (e.g., cortex, hippocampus) and plays a key role in cognitive functions, including memory, learning, and synaptic plasticity. It activates Gq/11 proteins, triggering downstream pathways like phospholipase C (PLC) activation, which regulates neuronal excitability and neurotransmitter release. Dysregulation of CHRM1 is implicated in neurological disorders such as Alzheimer’s disease, schizophrenia, and Parkinson’s disease.

CHRM1 antibodies are widely used in research to localize, quantify, and analyze receptor expression and function. They enable techniques like immunohistochemistry (IHC), Western blotting, and flow cytometry, aiding in the investigation of receptor distribution, signaling mechanisms, and therapeutic targeting. Monoclonal antibodies offer high specificity, while polyclonal versions may detect multiple epitopes. Validation parameters such as species reactivity, sensitivity, and cross-reactivity with other muscarinic subtypes (e.g., M2-M5) are critical to ensure experimental accuracy. Recent advancements in antibody engineering have improved their utility in studying CHRM1’s role in disease models and drug development, particularly for therapies aiming to modulate cholinergic signaling in neurodegenerative and psychiatric conditions.